Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305487 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
A Phase 3 study of Seasonal Allergic Rhinitis and Hay Fever, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
- 20
- Study locations
NCT00305487 is a Phase 3 study of Seasonal Allergic Rhinitis and Hay Fever that has completed, run by AstraZeneca. The registered enrollment target is 660 participants, roughly in line with the 627-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT00305487, a Phase 3 study of Seasonal Allergic Rhinitis and Hay Fever, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).
Conditions Studied
Interventions
- DRUG Ciclesonide nasal spray
Study Locations (20)
California
- Altana Pharma/Nycomed - Costa Mesa
- Altana Pharma/Nycomed - Huntington Beach
- Altana Pharma/Nycomed - Long Beach
- Altana Pharma/Nycomed - Los Alamitos
- Altana Pharma/Nycomed - Mission Viejo
- Altana Pharma/Nycomed - Orange
- Altana Pharma/Nycomed - Roseville
- Altana Pharma/Nycomed - San Diego
- Altana Pharma/Nycomed - San Diego
- Altana Pharma/Nycomed - San Jose
- Altana Pharma/Nycomed - Stockton
Colorado
- Altana Pharma/Nycomed - Colorado Springs
- Altana Pharma/Nycomed - Denver
- Altana Pharma/Nycomed - Englewood
- Altana Pharma/Nycomed - Lakewood, CO
Georgia
- Altana Pharma/Nycomed - Atlanta
- Altana Pharma/Nycomed - Gainesville
- Altana Pharma/Nycomed - Savannah
Alabama
- Altana Pharma/Nycomed - Birmingham
Arkansas
- Altana Pharma/Nycomed - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305487
The ClinicalTrials.gov registry entry for NCT00305487 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 627-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 1 intervention - of which Ciclesonide nasal spray is the first listed.
NCT00305487 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00305487 about?
NCT00305487 is a clinical study titled "Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)". The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).
What is the current status of trial NCT00305487?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2006-03. Estimated completion is 2006-10.
What conditions does trial NCT00305487 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis, Hay Fever.
What interventions are being tested in trial NCT00305487?
The interventions under investigation include: Ciclesonide nasal spray (DRUG).
Who is sponsoring clinical trial NCT00305487?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305487 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
COMPLETED · Phase 3
-
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
COMPLETED · Phase 3
-
Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
COMPLETED · Phase 3
-
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
-
Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.